Core Viewpoint - The performance of the SPDR S&P Biotech ETF (XBI) in 2026 will be significantly influenced by the Phase 3 data from Moderna (MRNA), Sarepta Therapeutics (SRPT), and Krystal Biotech (KRYS) as well as the regulatory environment under the FDA's new leadership [2][8]. Group 1: ETF Performance and Structure - The SPDR S&P Biotech ETF (XBI) has over 150 equal-weight positions and has increased by 46% over the past year, but it faces near-term challenges due to FDA staffing cuts that may slow the regulatory approval process [2][7]. - The fund has over $8 billion in assets, with 96% of its portfolio in healthcare, and is up about 2% year to date, although it has seen a 4% pullback in the last month [7]. - The equal-weight structure of XBI means that each clinical readout impacts the entire fund significantly, unlike cap-weighted indices [11]. Group 2: Company-Specific Insights - Moderna (MRNA), the largest position in XBI at 2.3% weight, anticipates Phase 3 data for norovirus and melanoma in 2026 and has rallied 82% year to date, partly due to a patent settlement [12]. - Krystal Biotech (KRYS) reported $204 million in net income for 2025, with VYJUVEK revenue growing 34% year over year, and has Phase 3 readouts expected before year-end [13]. - Sarepta Therapeutics (SRPT) is recovering from a 33% decline in ELEVIDYS revenue in Q4 2025 and aims to return to profitability in 2026, contingent on label rehabilitation and a recent launch in Japan [14]. Group 3: Regulatory Environment - The FDA's operational capacity under new leadership is a critical factor for XBI's performance, as consistent regulatory approval timelines are necessary to avoid valuation compression across its holdings [3][8]. - Concerns about FDA staffing reductions and restructuring have raised questions about review capacity, which could lead to a slower approval pipeline affecting small and mid-cap companies the hardest [9]. - Monitoring the FDA's published PDUFA action dates and advisory committee calendars is essential, as delays or unexpected refusals would signal potential issues [10].

Core Insights - CROSSJECT has made significant progress in the development and regulatory preparation of ZEPIZURE®, an injectable for managing epileptic seizures, with a focus on its proprietary ZENEO® needle-free auto-injector technology [1][5][6] Financial Performance - For the financial year ending December 31, 2025, CROSSJECT reported operating revenue of €14.9 million, a 12.2% increase from €13.3 million in 2024, primarily driven by BARDA invoicing which rose to €12.1 million from €8.2 million [3][14] - Operating expenses increased slightly to €26.5 million from €26.2 million in 2024, resulting in an operating loss of €11.6 million, an improvement from a loss of €13.0 million in 2024 [15][16] - The net loss for 2025 was €10.4 million, improved from €12.8 million in 2024, reflecting better revenue growth and disciplined expenditure management [16] Funding and Financial Structure - CROSSJECT received increased funding from BARDA, totaling $43.3 million, which supports regulatory and manufacturing activities [2][8] - The company reduced its bank debt by €2.7 million, with borrowings from credit institutions decreasing to €10.2 million from €12.9 million at the end of 2024 [4][18] - As of December 31, 2025, CROSSJECT had available cash of €5.1 million, supplemented by a €2.8 million research tax credit receivable, totaling €7.9 million [3][20] Regulatory and Operational Developments - In 2025, CROSSJECT achieved satisfactory stability results for ZEPIZURE® and produced additional validation batches, preparing for regulatory submissions [6][9] - The company is actively pursuing an Emergency Use Authorization (EUA) application in coordination with BARDA, aiming for commercial deliveries in 2026 and U.S. commercialization in 2027 [5][23] Strategic Direction - CROSSJECT is focusing on the development of its ZENEO® platform, including ZEPIZURE® Junior for pediatric use, and estimates the commercial potential of its emergency medicines portfolio could reach annual peak sales of around €1 billion [10][9] - The company has strengthened its governance and market visibility, with new coverage initiated by financial institutions and preparations for direct commercialization in the U.S. [12][13]

from. >> CNBC. Cures Defying Rare Disease premieres Thursday >> WELCOME BACK TO MONEY MOVERS.REPORTING FULL YEAR RESULTS FOR 25, A LOSS PER SHARE OF $0.72%, A LITTLE BETTER THAN EXPECTED. COMPANY ALSO ANNOUNCED IT'S RECEIVED ITS FIRST EVER LICENSE FROM THE NUCLEAR REGULATORY COMMISSION VIA A SUBSIDIARY, WHICH WILL ALLOW THE COMPANY TO SELL SOME ISOTOPE MATERIALS. JOINING US EXCLUSIVELY FROM THE COMPANY'S ISOTOPES TEST REACTOR NEAR LOCKHART, TEXAS, IS CEO JACOB DEWITT.JACOB, ALWAYS GOOD TO HAVE YOU. THANKS F ...

BitMart Global CEO Nenter Chow recently shared his views in an interview:Having transitioned from 17+ years in traditional finance to leading BitMart, Nenter discusses the industry’s shift from speculation toward utility, institutional infrastructure, and real financial plumbing.He highlights BitMart’s focus on omni-asset access including US equities and RWAs, full regulatory approval across all 50 US states, AI integration for operations, and education initiatives such as the UNICEF partnership. ...

BitMart Global CEO Nenter Chow recently shared his views in an interview:Having transitioned from 17+ years in traditional finance and Animoca Ventures to leading BitMart, Nenter discusses the industry’s shift from speculation toward utility, institutional infrastructure, and real financial plumbing.He highlights BitMart’s focus on omni-asset access including US equities and RWAs, full regulatory approval across all 50 US states, AI integration for operations, and education initiatives such as the UNICEF pa ...

Summary of Nuvalent FY Conference Call (March 04, 2026) Company Overview - **Company**: Nuvalent (NasdaqGS:NUVL) - **Focus**: Development of targeted therapies for cancer, specifically in the areas of ALK and ROS1 non-small cell lung cancer (NSCLC) [2][3] Key Milestones and Developments - **Zidesamtinib**: - NDA accepted by the FDA for TKI-pretreated ROS1 NSCLC with a PDUFA date set for September 18, 2026 [3] - Plans to submit data for potential line expansion in TKI-naive ROS1 in the second half of 2026 [3] - **Neladalkib**: - NDA submission planned for previously treated ALK NSCLC in the first half of 2026 [4] - Ongoing Phase 3 study (ALKAZAR) for TKI-naive ALK patients [4] - **HER2 Program**: - Progressing with the HER2 HEROEX-1 study, a Phase 1a/1b study [4] Market Insights - **ALK Market**: - Current market for previously treated ALK patients estimated at $500 million to $700 million, with potential for growth by driving durable responses [18] - Lorlatinib sales reached approximately $1 billion, with growth attributed to new front-line use [18] - **ROS1 Market**: - Current market size around $500 million, with potential to grow to $2.5 billion by improving patient outcomes and treatment durability [41] - Zidesamtinib shows a 93% response rate at a year-and-a-half landmark in previously treated patients [40] Competitive Landscape - **Neladalkib vs. Lorlatinib**: - Neladalkib aims to provide better outcomes for patients who have progressed on lorlatinib, addressing the limitations of CNS toxicity associated with lorlatinib [5][20] - The drug is designed to target a broader set of ALK mutations, potentially offering deeper and more durable responses [6][7] - **Regulatory Strategy**: - Plans to pursue registration for both Neladalkib and Zidesamtinib outside the U.S. based on strong enrollment and medical need [11][12] Commercial Readiness - **Sales Force**: - Building a team experienced in oncology and lung cancer, with a sales force expected to be in the range of 40-60 representatives [47] - **Patient Engagement**: - Strong collaboration with patient advocacy groups has contributed to rapid enrollment in clinical trials, indicating high demand for new therapies [30][36] Future Outlook - **Enrollment Expectations**: - Anticipated strong enrollment for the first-line trial, with historical data suggesting a timeline for data availability around 2029 [31][32] - **HER2 Inhibitor NVL-330**: - Positioned to address unmet needs in HER2-driven cancers, particularly with CNS penetrance advantages over existing therapies [56][57] Conclusion - Nuvalent is poised for significant developments in the oncology space with its innovative therapies targeting ALK and ROS1 pathways. The company is focused on addressing unmet medical needs, enhancing patient outcomes, and preparing for commercial launches in the near future.

Core Viewpoint - Paramount Skydance is optimistic about obtaining European regulatory approval for its $111 billion acquisition of Warner Bros. Discovery (WBD) [1] Regulatory Progress - Paramount's Chief Strategy Officer, Andy Gordon, stated that significant progress has been made in securing global regulatory clearances before the deal's closing [2] - Gordon mentioned that there are no statutory impediments to close the deal in the United States, and pre-notification discussions with the European Commission have already begun [3] - Germany and Slovenia have granted approval for the deal, indicating a positive sign from European regulators [3] European Commission's Stance - The European Commission has not formally acknowledged the acquisition yet but is expected to investigate a merger of this magnitude, which includes major franchises like Harry Potter and Game of Thrones [4] - Despite the extensive assets involved, a merged Paramount-WBD would control less than 20% of the European market, which may reduce regulatory challenges [4] Potential Delays - A Phase II probe by European regulators could significantly delay the deal, taking at least 90 days to complete [5] - Paramount has committed to increasing its offer for WBD by $0.25 each quarter after September 30 if the deal is not finalized, which could create complications for the company [5] U.S. Regulatory Concerns - In the U.S., Paramount is not entirely free from regulatory scrutiny, as California's Attorney General has announced a probe into the deal [6] - A Phase II investigation in the U.S. could prolong the regulatory process [6] Political Considerations - President Trump's position on the deal remains uncertain, although he has previously criticized Ellison and his team [7] - Despite this, market observers believe Trump may ultimately approve the deal due to his connections with the Ellison family [7]

Financial Data and Key Metrics Changes - For the full year 2025, net revenues were $719.9 million, with a modest decline of 2% year-over-year due to headwinds in legacy products [6][7] - Fourth quarter sales decreased 2% to $183.1 million from $186.5 million in the previous year, with net income reported at $24.4 million, or $0.51 per share, down from $38 million, or $0.74 per share in the prior year [11][14] - Adjusted net income for the fourth quarter was $34.2 million, or $0.73 per share, compared to $47.2 million, or $0.92 per share in the previous year [15] Business Line Data and Key Metrics Changes - BAQSIMI generated $185.4 million in revenue for the full year, up 12% year-over-year, while Primatene MIST sales rose 7% to $108.7 million [6][7] - In the fourth quarter, BAQSIMI sales grew 12% to $46.7 million, while Primatene MIST sales dropped 3% to $27.9 million [11][12] - Glucagon sales declined 45% to $14.1 million due to increased competition, and epinephrine sales decreased 9% to $17.1 million [12] Market Data and Key Metrics Changes - The company expects mid-single-digit unit growth for BAQSIMI in the U.S., offset by a planned reduction in international volume as it exits unprofitable markets [16][29] - The Atrovent market, associated with Ipratropium Bromide, was valued at $112 million last year, with expectations of meaningful market share due to 180 days of exclusivity [32] Company Strategy and Development Direction - The company aims to transition towards a portfolio anchored in high-value proprietary and biosimilar assets, with significant investments in R&D and manufacturing capabilities [5][9] - The expansion of the U.S. manufacturing facility in Rancho Cucamonga is a critical part of the long-term strategy, expected to quadruple production capacity [9][18] - The company plans to ramp up spending on clinical trials and materials for inhalation and proprietary pipeline products, with a focus on oncology, ophthalmology, and immunology [18][25] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of resilient commercial momentum and strategic pipeline progress, with expectations for consolidated revenue growth in the mid-to-high single-digit range for 2026 [20][17] - Gross margins are expected to be lower in 2026 due to pricing pressures on glucagon and epinephrine, alongside increased input costs [17][39] Other Important Information - The company has over $300 million in cash and short-term investments, with plans to utilize a portion for stock buybacks while also exploring business development opportunities [18][40] - The company achieved several major regulatory milestones in 2025, including FDA approvals for iron sucrose, teriparatide, and Ipratropium Bromide HFA [20][8] Q&A Session Summary Question: Development path for AMP-110 and business development priorities - Management has not yet engaged the FDA regarding AMP-110 but is preparing the program [24] - Business development will focus on areas where the company has or plans to have a presence, including endocrinology and oncology [25] Question: BAQSIMI expectations for 2026 and international sales - BAQSIMI is expected to see mid-single-digit growth in the U.S., with international sales declining in the second half of the year [29][30] Question: Gross margins and buyback plans - BAQSIMI growth will help margins, but declines in glucagon and epinephrine will offset this [39] - The company plans to continue buybacks, with $75 million as a potential high end for the year [40] Question: Competition for Primatene MIST and filing cadence - The patent for Primatene MIST has expired, but management does not anticipate significant competition [45] - The company expects to have 2 filings late this year and 2-3 filings next year [47] Question: Updates on Nanjing Anji in-licensed assets - The company is in the preclinical stage for these assets and is optimistic about their potential [50][51]

Financial Data and Key Metrics Changes - Sempra reported fourth quarter 2025 GAAP earnings of $352 million or $0.54 per share, down from $665 million or $1.04 per share in Q4 2024 [10] - Full year 2025 GAAP earnings were $1,796 million or $2.75 per share, compared to $2,817 million or $4.42 per share in 2024 [10] - Adjusted earnings for Q4 2025 were $841 million or $1.28 per share, down from $960 million or $1.50 per share in Q4 2024, while full year 2025 adjusted earnings were $3,066 million or $4.69 per share, up from $2,969 million or $4.65 per share in 2024 [10][11] Business Line Data and Key Metrics Changes - At Sempra Texas, there was an increase of $80 million in equity earnings due to higher invested capital and customer growth, offset by higher interest expense and depreciation [11] - Sempra California experienced a decrease of $213 million primarily from lower income tax benefits and higher net interest expense, despite a $148 million increase in CPUC-based operating margin [11] - Sempra Infrastructure saw a $123 million increase from higher asset and supply optimization and transportation results, partially offset by lower income tax benefits [11] Market Data and Key Metrics Changes - Sempra's capital plan for 2026-2030 totals $65 billion, a 17% increase from the previous year's plan, with 95% targeted for utility investments [6][15] - The projected rate base is expected to grow from $57 billion in 2025 to $97 billion in 2030, representing an 11% CAGR [17] - Oncor's rate base is projected to grow at an 18% CAGR over the plan period, while California's rate base is expected to grow more modestly [17] Company Strategy and Development Direction - The company introduced five value creation initiatives aimed at simplifying the business model, mitigating risk, and improving financial strength [5] - A focus on utility investments with improved returns and a significant capital plan to support growth in Texas, particularly in transmission projects [5][15] - The company aims to transition to a more pure-play utility holding company, with regulated earnings expected to comprise approximately 95% of total earnings by 2027 [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the quality and certainty of future earnings and cash flows, with a reaffirmation of the 2026 adjusted EPS guidance range of $4.80-$5.30 [22] - The company highlighted the importance of regulatory matters and ongoing efforts to improve efficiencies and modernize operations in California [31][34] - Management noted that the growth seen in Texas is expected to complement the operations in California, creating a balanced growth strategy [72] Other Important Information - The company is tracking $9 billion of upside opportunities within the capital plan period, which could enhance future growth [6][16] - Sempra aims to maintain a strong balance sheet and investment-grade credit ratings, with the pending SI Partners transaction being a key driver [19][94] - The company is committed to returning capital to shareholders, targeting annual dividend growth of 2%-4% over the plan period [24] Q&A Session All Questions and Answers Question: Clarification on 2023 guidance and growth expectations - Management indicated that the $9 billion upside opportunities could help move the company into the upper half of the 2030 guidance range, emphasizing improved quality and certainty of future earnings [28][30] Question: Insights on California's contribution to earnings growth - Management acknowledged that California's growth is moderated due to approved attrition from the last GRC, but there are ongoing efforts to improve efficiencies and drive value [34] Question: Timeline for $9 billion upside opportunities in Texas - Management noted that the $9 billion upside capital opportunities are expected to layer in around 2028, 2029, and 2030, with a focus on regulatory approvals [43][49] Question: Data center pipeline and construction challenges - Management confirmed that there is significant interest from data center developers, with ongoing projects and efforts to meet the growing demand for service [82][86] Question: Credit metrics and balance sheet management - Management highlighted the importance of maintaining a strong balance sheet, with a focus on improving credit metrics and eliminating the need for common equity in the base plan [93][94]

Alliant Energy Corporation Q4 2025 Earnings Call February 20, 2026 2025 Q4 Earnings Call 2 ALLIANT ENERGY 2025 Highlights 6.3% 10-year earnings CAGR | Financial Results | 2025 | 2024 | | --- | --- | --- | | GAAP net income (in millions) | $810 | $690 | | GAAP earnings per share (EPS) | $3.14 | $2.69 | | Ongoing EPS | $3.22 | $3.04 | Cautionary Statements Forward-looking Statements The information regarding earnings per share guidance, dividend target, earnings per share growth, load growth, capital expendit ...